Immix Biopharma (NASDAQ:IMMX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright's target price would suggest a potential upside of 219.63% from the company's previous close. HC Wainwright also issued estimates for Immix Biopharma's Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.65) EPS.
Immix Biopharma Stock Performance
IMMX stock traded up $0.13 on Wednesday, hitting $2.19. 293,858 shares of the company's stock were exchanged, compared to its average volume of 154,554. The firm has a 50 day moving average price of $1.88 and a two-hundred day moving average price of $1.94. Immix Biopharma has a 12-month low of $1.26 and a 12-month high of $3.00. The stock has a market cap of $61.05 million, a P/E ratio of -2.58 and a beta of 0.31.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.09. Sell-side analysts expect that Immix Biopharma will post -0.87 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Immix Biopharma stock. Jane Street Group LLC acquired a new stake in shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 17,523 shares of the company's stock, valued at approximately $39,000. Jane Street Group LLC owned about 0.06% of Immix Biopharma at the end of the most recent reporting period. 11.26% of the stock is currently owned by institutional investors and hedge funds.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
See Also
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
